Revolution Medicines, Inc. cash flow to debt ratio of -565.68% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Revolution Medicines, Inc.'s free cash flow has decreased 60.94% from $-567.74M last year to $-913.73M, signaling decreasing performance

Revolution Medicines, Inc.'s debt to equity ratio is 0.29, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Revolution Medicines, Inc.'s debt has increased relative to shareholder equity from 0.06 last year to 0.29 today, signaling weakened financials

Revolution Medicines, Inc. has negative EBITDA, making leverage ratio unreliable

Revolution Medicines, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Revolution Medicines, Inc. has insufficient data to evaluate this check.

Revolution Medicines, Inc.'s short-term assets of $2.08G exceed its short-term liabilities of $290.42M

Revolution Medicines, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Revolution Medicines, Inc.'s return on equity of -83.22%, is lower than 15.00%, indicating bad performance

Revolution Medicines, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Revolution Medicines, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Revolution Medicines, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Revolution Medicines, Inc. has negative free cash flow, indicating cash burn

Revolution Medicines, Inc.'s yearly earnings has decreased 88.52% since last year from $-600.09M to $-1.13G, signaling decreasing performance

Revolution Medicines, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -70.02% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Revolution Medicines, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Revolution Medicines, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Revolution Medicines, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Revolution Medicines, Inc. has insufficient data to evaluate this check.

Revolution Medicines, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Revolution Medicines, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Revolution Medicines, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Revolution Medicines, Inc. has insufficient data to evaluate this check.

Revolution Medicines, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Revolution Medicines, Inc. has a price-to-book ratio of 24.05x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Revolution Medicines, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue